Page 1

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30 , 2021 November 8 , 2021 Reports Net Revenues of $ 112.2 Million for the Three Months Ended September 30 , 2021 RANCHO CUCAMONGA , CA / ACCESSWIRE / November 8 , 2021 / Amphastar Pharmaceuticals , Inc. ( NASDAQ : AMPH ) ( " Amphastar " or the " Company " ) today reported results for the three months ended September 30 , 2021 . Third Quarter Highlights • Net revenues of $ 112.2 million for the third quarter • GAAP net income of $ 29.5 million , or $ 0.59 per share , for the third quarter • Adjusted non - GAAP net income of $ 23.0 million , or $ 0.46 per share , for the third quarter Dr. Jack Zhang , Amphastar's President and Chief Executive Officer , commented : " We delivered record sales due to the continued momentum driven by the strength of our glucagon , Primatene Mist and our epinephrine products . These products should continue to be the primary drivers of growth until we receive further approvals for products in our pipeline , which we project will happen in 2022. " Three Months Ended September 30 , Nine Months Ended September 30 , 2021 2020 2021 2020 Net revenues GAAP net income attributable to Amphastar Adjusted non - GAAP net income attributable to Amphastar * ( in thousands , except per share data ) $ 112,198 $ 83,431 $ 316,881 $ 253,925 $ 29,548 $ 3,919 $ 42,356 $ 7,676 $ 22,998 $ 7,629 $ 47,166 $ 23,622 GAAP diluted EPS attributable to Amphastar stockholders $ 0.59 $ 0.08 $ 0.85 $ 0.16 Adjusted non - GAAP diluted EPS attributable to Amphastar stockholders * $ 0.46 $ 0.15 $ 0.95 $ 0.48 * Adjusted non - GAAP net income attributable to Amphastar and Adjusted non - GAAP diluted EPS attributable to Amphastar stockholders are non - GAAP financial measures . Please see the discussion in the section entitled " Non - GAAP Financial Measures " and the reconciliation of GAAP to non- GAAP financial measures in Table III of this press release . Third Quarter Results Three Months Ended